Citigroup Inc Allakos Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Allakos Inc. stock. As of the latest transaction made, Citigroup Inc holds 101 shares of ALLK stock, worth $128. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101

Previous 42,160 99.76%

Holding current value

$128

Previous $42,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.54 - $0.92 $22,711 - $38,694	-42,059 Reduced 99.76%	101 $0
Q2 2024 Aug 12, 2024	SELL	$1.0 - $1.45 $232,720 - $337,444	-232,720 Reduced 84.66%	42,160 $42,000
Q1 2024 May 10, 2024	BUY	$1.02 - $3.23 $253,457 - $802,616	248,488 Added 941.53%	274,880 $346,000
Q4 2023 Feb 09, 2024	SELL	$1.72 - $3.18 $727,943 - $1.35 Million	-423,223 Reduced 94.13%	26,392 $72,000
Q3 2023 Nov 09, 2023	SELL	$2.13 - $5.55 $198,245 - $516,555	-93,073 Reduced 17.15%	449,615 $1.02 Million
Q2 2023 Aug 10, 2023	SELL	$3.6 - $5.25 $1.05 Million - $1.53 Million	-292,211 Reduced 35.0%	542,688 $2.37 Million
Q1 2023 May 11, 2023	BUY	$4.3 - $8.27 $879,694 - $1.69 Million	204,580 Added 32.46%	834,899 $3.72 Million
Q4 2022 Feb 09, 2023	BUY	$5.66 - $8.42 $1.55 Million - $2.3 Million	273,254 Added 76.53%	630,319 $5.31 Million
Q3 2022 Nov 10, 2022	BUY	$3.02 - $6.12 $29,239 - $59,253	9,682 Added 2.79%	357,065 $2.19 Million
Q2 2022 Aug 10, 2022	BUY	$2.6 - $6.14 $886,506 - $2.09 Million	340,964 Added 5311.79%	347,383 $1.09 Million
Q1 2022 May 12, 2022	SELL	$5.08 - $9.81 $570,321 - $1.1 Million	-112,268 Reduced 94.59%	6,419 $37,000
Q4 2021 Feb 10, 2022	BUY	$8.55 - $111.89 $592,318 - $7.75 Million	69,277 Added 140.21%	118,687 $1.16 Million
Q3 2021 Nov 10, 2021	BUY	$76.53 - $110.43 $3.78 Million - $5.46 Million	49,410 New	49,410 $5.23 Million

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account